SCHEMBL7819709

SCHEMBL7819709

CC(=O)[C@H](CNC(=O)Cc1cccc(-c2ccccn2)c1)NC(=O)[C@H](CC(C)C)NC(=O)c1ccc2ncsc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 6/20 0.43
▸ CTSS P25774 3/20 0.43
▸ CTSB P07858 2/20 0.43
▸ TAS1R3 Q7RTX0 2/20 0.40
▸ TAS1R1 Q7RTX1 2/20 0.40
▸ CTSK P43235 2/20 0.38
▸ PSMB10 P40306 1/20 0.36
▸ PSMB2 P49721 1/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ CTSV O60911 2/20 0.36
▸ SMYD3 Q9H7B4 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CCR1 P32246 1/20 0.35
▸ CTSD P07339 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7617864 0.91 CTSL (0.43) CTSLCTSSCTSBTAS1R3TAS1R1
SCHEMBL7461611 0.89 CTSL (0.47) CTSLCTSSCTSBTAS1R3TAS1R1
SCHEMBL7609931 0.89 CTSL (0.43) CTSLCTSSCTSBTAS1R3TAS1R1
SCHEMBL7473345 0.77 TAS1R3 (0.54) CTSLCTSSCTSBTAS1R3TAS1R1
SCHEMBL6927425 0.77 CTSL (0.55) CTSLCTSSCTSBCTSKCTSV
SCHEMBL7815927 0.76 CYP3A4 (0.35) CTSLCTSSCTSBTAS1R3TAS1R1
SCHEMBL7617860 0.76 CYP3A4 (0.36) CTSLCTSSCTSBTAS1R3TAS1R1
SCHEMBL7462272 0.76 CTSL (0.50) CTSLCTSSCTSBTAS1R3TAS1R1
SCHEMBL7609927 0.76 CTSL (0.36) CTSLCTSSCTSBTAS1R3TAS1R1
SCHEMBL6927525 0.75 CTSL (0.49) CTSLCTSSCTSBCTSKCTSV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1068304-A4 TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY SMITHKLINE BEECHAM CORP (US) 2001-05-09 — — EP claimed
EP-1068304-A1 TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY SMITHKLINE BEECHAM CORPORATION (US) 2001-01-17 — — EP claimed
WO-1999053039-A1 TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY SMITHKLINE BEECHAM CORPORATION (US) 1999-10-21 — — WO claimed
EP-1068304-A4 TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY SMITHKLINE BEECHAM CORP (US) 2001-05-09 — — EP disclosed
EP-1068304-A1 TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY SMITHKLINE BEECHAM CORPORATION (US) 2001-01-17 — — EP disclosed
WO-1999053039-A1 TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY SMITHKLINE BEECHAM CORPORATION (US) 1999-10-21 — — WO disclosed
Send feedback